US–China Strategic Competition The Quest for Global Technological Leadership

whitePaper | May 1, 2022

Customer experience (CX) in government is about more than any single web form, survey, portal, or online claims submission. CX also considers the perceptions, preferences, and sentiments for an individual, business, or organization as they interact across the various channels of an agency’s program or service.

whitePaper | December 10, 2019

The Trump administration, members of Congress from both parties, and many states have introduced proposals to combat high drug prices. Too often missing from these reform efforts, however, is a clear understanding of a root cause of the crisis: the suppression of fair market competition through various forms of monopoly. This white paper examines and proposes solutions for the two main ways that monopoly drives up the costs and lowers the quality of prescription drugs: increasing corporate concentration in the pharmaceutical industry, and the monopoly markets for individual drugs created by a deeply flawed and increasingly abused patent and regulatory system.

whitePaper | March 13, 2023

The intensifying impacts of climate change create challenges for the environment, public health, and the economy. President Biden set an ambitious target for the United States to achieve a 50-52 percent reduction in annual greenhouse gas emissions1 from 2005 levels by 2030, and is mobilizing a whole-of-government approach to climate action, capitalizing on major legislative achievements, through policies in the 2024 fiscal year budget that hasten and smooth the transition to a net-zero economy.

whitePaper | April 15, 2022

This IDC White Paper looks at the evolution of the Dutch cloud market. It assesses organisations' progress on their digital transformation (DX) journeys and where they see themselves in terms of cloud and DevOps maturity. The paper is based on survey data and research and analysis conducted by IDC on behalf of Capgemini.

whitePaper | February 12, 2020

Both the U.S. Government and biopharmaceutical industry have been central engines for developing new medical treatments and cures, thereby lowering the effective price of better health for patients worldwide. The sector has done so by being both the world leader in these biopharmaceutical cures and treatments as well as the source of the returns that are required to fund new medical R&D investments.

whitePaper | December 26, 2019

Transforming the way governments serve the public is about more than choosing the right technologies. This level of change requires agencies to rethink how they engage their customers — from citizens and external partners to the frontline employees assisting the public.